Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Revenues:
Revenues	$ 148,489,000	$ 128,568,000
Cost of revenues	90,618,000	66,015,000
Gross profit	57,871,000	62,553,000
Operating expenses:
Research and development	19,605,000	18,816,000
Patent litigation expense	4,278,000	4,038,000
Selling, general and administrative	29,717,000	21,233,000
Total operating expenses	53,600,000	44,087,000
Income from operations	4,271,000	18,466,000
Other income (expense), net	149,456,000	(48,000)
Interest income	276,000	255,000
Interest expense	(283,000)	(39,000)
Income before income taxes	153,720,000	18,634,000
Provision for income taxes	48,278,000	6,269,000
Net income	105,442,000	12,365,000
Net Income per share:
Basic (in Dollars per share)	$ 1.59	$ 0.19
Diluted (in Dollars per share)	$ 1.55	$ 0.18
Weighted average common shares outstanding:
Basic (in Shares)	66,487,470	65,122,240
Diluted (in Shares)	68,178,355	67,907,263
Global Division Sales [Member]
Revenues:
Revenues	101,636,000	123,265,000
Impax Division Sales [Member]
Revenues:
Revenues	$ 46,853,000	$ 5,303,000